H

ello, everyone, and welcome to the middle of the week, which arrived rather quickly, yes? This is a good sign, since it means the week is barreling along as you continue your struggle after the holiday break to get in sync with the usual daily routines. So have heart, the weekend is not that far off. This is the encouragement we offered our shortest person as the schoolhouse bus arrived. Easier said than done, though. In any event, time to get cracking. So here are a few items of interest to push you forward. Hope your day is splendid and, of course, do keep in touch …

The U.K.’s National Institute for Health and Care Excellence issued final draft guidance approving the GlaxoSmithKline (GSK) gene therapy, Strimvelis, for an ultra-rare immune deficiency condition known as bubble boy syndrome. At nearly $717,000, the list price for the one-time treatment makes Strimvelis the most expensive medicine ever recommended in the U.K., Bloomberg News notes.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy